(2S,3S)-methyl-phenylalanine | 124192-91-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,3S)-methyl-phenylalanine
• 英文别名: N-methylphenyl-alanine；(2S)-2-(N-methylanilino)propanoic acid
• CAS: 124192-91-2
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD09704699
• 分子量: 179.219
• InChiKey: BEIMQZCXRUNTAS-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] COMPOSÉS ARYLES TRICYCLIQUES CONDENSÉS UTILES POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：SCHERING CORP

  公开号：WO2010132538A1

  公开（公告）日：2010-11-18

  The present invention relates to novel Fused Tricyclic Aryl Compounds, compositions comprising at least one Fused Tricyclic Aryl Compound, and methods of using the Fused Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient.

  本发明涉及新型融合三环芳基化合物、包含至少一种融合三环芳基化合物的组合物，以及使用这些融合三环芳基化合物治疗或预防患者中HCV感染的方法。
• Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
  申请人：Novaspin Biotech GmbH

  公开号：US20030114362A1

  公开（公告）日：2003-06-19

  The subject matter of the present invention is a cyclic or linear tetra- or pentapeptide binding to somatostatin receptors. The compounds of the invention are characterised in that they contain the radical of an amino carboxylic acid bearing a five-membered ring in the peptide backbone which may optionally contain O, S, Se, N, or P. These compounds are easy to prepare and display increased stability against peptidases. The compounds of the present invention induce apoptosis of tumour cells and the use of said compounds for cancer therapy is described. In particular, the compounds are characterised in that they are active even against tumour cells displaying resistance against other somatostatin derivatives such as octreotide. In addition, the use of the compounds of the invention for tumour diagnosis by means of positron-emission tomography is described, as well as their use as agents against neurogenic inflammation.

  本发明涉及一种循环或线性的四肽或五肽，可结合生长抑素受体。本发明的化合物特征在于它们含有氨基羧酸的基团，其肽骨架中带有一个五元环，该五元环可以选择性地含有O、S、Se、N或P。这些化合物易于制备，并且对肽酶具有更高的稳定性。本发明的化合物能够诱导肿瘤细胞凋亡，并描述了这些化合物在癌症治疗中的应用。特别是，这些化合物的特点在于它们甚至对于其他生长抑素衍生物（如奥曲肽）产生抗药性的肿瘤细胞也具有活性。此外，本发明的化合物的用途还包括通过正电子发射断层扫描进行肿瘤诊断，以及作为神经源性炎症的药物。
• Photoinitiator and photopolymerizable composition using the same
  申请人：Hitachi Chemical Co., Ltd.

  公开号：EP0295044A2

  公开（公告）日：1988-12-14

  A photoinitiator composition comprising (1) an aminobenzylidene carbonyl compound and (2) an N-­aryl-α-amino acid is suitable for use in a photo­polymerizable composition comprising (a) an addition-­polymerizable compound having a boiling point of 100°C or higher at an atmospheric pressure and (b) said photoinitiator composition.

  由(1)亚氨基苄基羰基化合物和(2)N-芳基-α-氨基酸组成的光引发剂组合物适用于光聚合组合物，该组合物包括(a)在大气压下沸点为 100°C 或更高的可加成聚合的化合物和(b)所述光引发剂组合物。
• Sustained-release preparation
  申请人：——

  公开号：US20020058622A1

  公开（公告）日：2002-05-16

  According to a first embodiment, there is provided a sustained-release preparation comprising a water-insoluble or slightly water-soluble polyvalent metal salt of a water-soluble physiologically active substance which is not an endothelin antagonist, and a biodegradable polymer. The sustained-release preparation of the first embodiment is highly efficient in incorporating the water-soluble physiologically active substance and suppresses the initial burst of the water-soluble physiologically active substance. The sustained-release preparation of the present invention is capable of releasing the water-soluble physiologically active substance while retaining its bioactivity after administration in vivo. Furthermore, the water-soluble physiologically active substance in the sustained-release preparation is kept stable for a long period of time, with little loss of bioactivity. According to a second embodiment, there is provided a sustained-release preparation comprising an anti-endothelin substance and a biodegradable polymer. The sustained-release preparation of the present invention sustainedly releases an anti-endothelin substance, serving well in the treatment of endothelin-associated diseases.

  根据第一个实施方案，提供了一种缓释制剂，该制剂包含一种不溶于水或微溶于水的水溶性生理活性物质的多价金属盐，该生理活性物质不是内皮素拮抗剂，还包含一种可生物降解的聚合物。第一实施方案中的缓释制剂能高效地掺入水溶性生理活性物质，并抑制水溶性生理活性物质的初始迸发。本发明的缓释制剂能够释放水溶性生理活性物质，同时在体内给药后保持其生物活性。此外，本发明的缓释制剂中的水溶性生理活性物质可保持长期稳定，生物活性损失小。 根据第二个实施方案，本发明提供了一种由抗内皮素物质和生物可降解聚合物组成的缓释制剂。本发明的缓释制剂可持续释放抗内皮素物质，在治疗内皮素相关疾病中发挥良好作用。
• COMPOUNDS AND COMPOSITIONS WHICH INHIBIT BONE RESORPTION
  申请人：THE UNIVERSITY OF MELBOURNE

  公开号：EP0561877A1

  公开（公告）日：1993-09-29